

In the Claims:

Kindly rewrite claims 4, 5 and 7 as follows:

4. (Amended) Method of claim 1, wherein the potential inhibitors have been tailored by computer designing and/or produced by a chemical process of production.
5. (Amended) A pharmaceutically acceptable inhibitor of PHGPx from human tissue obtainable by the method according to claim 1 and useful for male fertility control.
7. (Amended) Use of an inhibitor of PHGPx according to claim 5 or of a pharmaceutical composition comprising said inhibitor of PHGPx in a method for reversibly blocking male fertility.


REMARKS

The claims of the above referenced application (as they have been amended under Article 34 and are attached as annexes to the International Preliminary Examination Report) have been amended to remove all multiple dependencies. No new matter has been added. Accordingly, an early examination of the application is respectfully requested.

The Commissioner is authorized to charge any additional fees that may be required to Deposit Account No. 50-0320.

Respectfully submitted,
FROMMER LAWRENCE & HAUG LLP

By:


Ronald R. Santucci
Reg. No. 28,988
(212) 588-0800

APPENDIX: (claims with markings)

4. (Amended) Method of claim 1[, 2 or 3], wherein the potential inhibitors have been tailored by computer designing and/or produced by a chemical process of production.

5. (Amended) A pharmaceutically acceptable inhibitor of PHGPx from human tissue obtainable by the method according to claim 1[, 2, 3 or 4] and useful for male fertility control.

7. (Amended) Use of an inhibitor of PHGPx according to claim 5 or of a pharmaceutical composition comprising said inhibitor of PHGPx [according to claim 6] in a method for reversibly blocking male fertility.